stockrow
Saturday 7 November 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024.
- Revenue
- −32.1%
- EPS
- −15.4%
- Free cash flow
- −28.0%
Quarter to June 2026, against a year earlier
1.15
0.08
+7.48%
Follow PROK
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 1 | 1 | +1,075.0% | 1 | 0 | 63 | +312.8% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | (27) | (55) | (147) | (129) | (164) | (151) | (167) | +41.2% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (215,701.32) | (16,931.47) | (20,388.39) | (16,931.5) pt | ||||||
| Net income | — | 0 | — | — | (27) | (55) | (148) | (135) | (163) | (152) | (166) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (0.23) | (0.57) | (0.62) | (0.52) | (0.55) | +31.2% | ||||||
| Cash flow | — | — | — | — | 0.00 | (0.82) | (1.25) | (1.46) | (1.29) | (0.90) | (0.76) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | (0.08) | (0.03) | (0.55) | (0.30) | 0.02 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | (0.90) | (1.28) | (2.01) | (1.59) | (0.87) | (0.76) | n/m | ||||||
| Book value | — | — | — | — | 0.00 | 0.44 | (17.82) | (17.88) | (10.16) | (7.55) | (4.74) | n/m | ||||||
| Shares, m | — | — | — | — | — | 62 | 62 | 62 | 98 | 134 | 149 | +21.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 335.98 | 262.28 | 168.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 33.98 | 40.72 | 17.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 1.24 | (0.26) | (0.24) | 0.5 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (25) | (50) | (77) | (90) | (126) | (120) | (141) | +36.7% | |||||
| Capex | — | — | — | — | (5) | (5) | (2) | (34) | (30) | 3 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | (31) | (55) | (79) | (124) | (156) | (117) | (142) | +30.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 15 | 494 | 349 | 360 | 250 | 167 | +102.2% | |||||
| Net debt | — | — | — | — | — | (21) | (490) | (363) | (358) | (270) | (182) | +90.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | 27 | (1,097) | (1,103) | (995) | (1,011) | (884) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (273.69) | (38.70) | (7.56) | (14.20) | (17.77) | (27.10) | (17.8) pt | |||||
| ROIC | — | — | — | — | 0.00 | (541.65) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | 0.00 | 20.20 | 3.22 | 5.83 | 6.88 | 8.92 | +6.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 87 | 163 | 204 | 231 | — | +196.2% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
ProKidney Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AVIR Atea Pharmaceuticals, Inc. | $338.5M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $337.8M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $335.4M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| IRD Opus Genetics, Inc. | $333.2M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| FENC Adherex Technologies Inc. | $329.3M | — (loss-making) | 34.1× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| PROK ProKidney Corp. | $322.0M | — (loss-making) | — (loss-making) | −32.13% (below 0%: shrinking) | n/m | −28.03% (below 0%: shrinking) | 100.00% | (32,248.67%) | |
| EIKN Eikon Therapeutics, Inc. | $316.3M | — (loss-making) | — | — | n/m | +15.18% (above 0%: growing) | — | 0.00% | Compare |
| ALEC Alector, Inc. | $309.9M | 6.6× | — (loss-making) | +4,895.89% (above 0%: growing) | n/m | +25.73% (above 0%: growing) | 100.00% | 76.04% | Compare |
| XFOR X4 Pharmaceuticals, Inc. | $304.4M | — (loss-making) | — (loss-making) | +63.12% (above 0%: growing) | n/m | +27.45% (above 0%: growing) | 82.18% | (694.37%) | Compare |
| Median of peers | $331.2M | — | — | +85.18% | — | +26.59% | 82.18% | (47.97%) |
Pay and ownership Proxy statement filed 17 April 2026
Ownership
Directors and executive officers, together
38.80% of the votes
Pablo Legorreta
35.50% of the votes
Tolerantia, LLC
35.40% of the votes
Control Empresarial de Capitales, S.A. de C.V. (formerly Inversora Carso, S.A. de C.V.)
24.50% of the votes
Morgan Stanley Investment Management Inc.
2.80% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement